Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк., Санофи БайотекнолоджиfiledCriticalРидженерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2019/048460external-prioritypatent/WO2020047029A1/en
Publication of EA202190634A1publicationCriticalpatent/EA202190634A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
В настоящем документе раскрыты способы лечения субъектов, страдающих ревматоидным артритом (РА), с помощью человеческого антитела против интерлейкина 6 (ИЛ-6) или его антигенсвязывающего фрагмента.Disclosed herein are methods of treating subjects suffering from rheumatoid arthritis (RA) with a human anti-interleukin 6 (IL-6) antibody or antigen-binding fragment thereof.
EA202190634A2019-08-192019-08-28
METHODS AND COMPOSITIONS FOR TREATMENT OF SUBJECTS SUFFERING WITH RHEUMATOID ARTHRITIS
EA202190634A1
(en)
HUMANIZED ANTIBODY FOR TREATMENT OR PREVENTION OF COGNITIVE DISORDERS, METHOD OF ITS OBTAINING AND AN AGENT FOR TREATMENT OR PREVENTION OF COGNITIVE DISORDERS WITH ITS APPLICATION